Dosing JAK Inhibitors in Patients With Myelofibrosis
For most JAK inhibitors dosing starts at the maximum safe dose, while ruxolitinib often requires lower initial doses and dose reductions over the first 12 weeks when cytopenias typically worsen before partially improving, warranting consideration of earlier switching to alternative JAK inhibitors instead of pushing through transfusions.
EP: 1.Diagnosing Myelofibrosis
EP: 2.Assessing Risk Level of Patients With Myelofibrosis
EP: 3.Educational Resources for Patients Diagnosed With Myelofibrosis
EP: 4.Key Patient Goals for Myelofibrosis Management
EP: 5.Management of Anemia in Patients With Myelofibrosis
EP: 6.Clinical Data on the Approved JAK Inhibitors for Treatment of Myelofibrosis
EP: 7.Adverse Events Seen With JAK Inhibitors for Myelofibrosis
EP: 8.Assessing Treatment Response in Patients With Myelofibrosis
EP: 9.Best Approaches to Switching Therapies for a Patient With Myelofibrosis
EP: 10.Dosing JAK Inhibitors in Patients With Myelofibrosis
EP: 11.Key Takeaways for Patients With Myelofibrosis
Oncology Nurses Provide Patients an Avenue to Supportive Care
November 12th 2019Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that isn't the reality of what id can do for patients. And oncology nurses can help guide patients to the right supportive care for them.
Hyman B. Muss Discusses the Importance of Nurses in Treating Pregnant Women With Breast Cancer
March 23rd 2016Hyman B. Muss, MD, professor of medicine at the University of North Carolina School of Medicine, discusses the vital roles that nurses play when it comes to treating pregnant women with breast cancer.
Kimberly J. Van Zee on Nomograms Helping in DCIS Treatment Decision-Making
March 18th 2016Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's newly-developed nomogram that can help women make treatment decisions about ductal carcinoma in situ (DCIS).
